PCAS

Earnings Release • Jul 19, 2016

SUSTAINED GROWTH IN FOR THE 1 NET SALES ST HALF OF 2016

Longjumeau, July 19, 2016

PCAS (Euronext Paris : PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the 1st half of 2016.

The PCAS Group's consolidated net sales totaled the same period in the previous €100.7 million in the 1st half of 2016, 11.5% up on financial year (+10.0% at a constant exchange rate).

in millions of euros	2016	2015	% change	2016 At a constant exchange rate	% change
Net sales at June 30	100.7	90.3	11.5%	99.3	10.0%
Pharmaceutical Synthesis	68.6	60.5	13.3%	67.3	11.2%
Fine Specialty Chemicals	32.1	29.8	7.9%	32.1	7.6%

Vincent Touraille, Chief Executive Officer of PCAS, explains: in which our net sales have been heading at the end of the first half of the year. our sales growth targets, excluding growth through acquisition, both in Pharmaceutical Synthesis an in Fine Specialty Chemicals, and an increase in our results of 2016 taking into account, as planned in order to cope with a sustainable increase in the "We are very satisfied with the direction pecialty for 2016 as a whole, r planned, the costs of the measures taken to optimize site organization the activity". We can also confirm and , results for the 1st half

Pharmaceutical Synthesis

Pharmaceutical synthesis activities in Health generated constant exchange rate), particularly sustained by the Exclusive activity. €68.6 million, up 13.3% on 2015 (+11.2% at a

Fine specialty chemicals

Net sales of Fine Specialty Chemicals totaled exchange rate), this activity growing both in Performance Additives and Advanced Specialty Chemicals. €32.1 million, up 7.9% on 2015 (+7.6% at a constant

NEXT FINANCIAL DISCLOSURE:

1 st half 2016 earnings report, September 7, 2016

About PCAS

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R& preferred industrial partner of market proprietary products and solutions in leading strong potential: Protéus in biotechnology and Enersens in high high standard of performance, PCAS achieved net sales of people in six countries. R&D and a wide international presence, PCAS is the market-leading major global groups. The company offers a growing range of leading-edge segments, and also includes two subsidiaries with high-performance insulation. With a particularly €179.1 million in 2015 and employs nearly 900 D leading edge very performance

For more information about PCAS: www.pcas.com

PCAS

Vincent Touraille / Eric Moissenot PCAS

Tél. : +33 1 69 79 61 32 www.pcas.com

NewCap NewCap

Emmanuel Huynh / Louis NewCap Financial Communication & -Victor Delouvrier & investors relations

. Tél. : +33 1 44 71 98 53 pcas@newcap.eu